The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Continuous Bio-Manufacturing Skid Market Expected To Scale Between 2026 And 2030?
The continuous bio-manufacturing skid market has seen rapid expansion in recent years. It is anticipated to increase from $1.99 billion in 2025 to $2.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. The historical growth of this market can be ascribed to several factors, including the rising volumes of biologics production, an early shift from batch to continuous processing, increased adoption of modular manufacturing concepts, the expansion of facilities for vaccine and enzyme production, and a growing demand for flexible manufacturing setups.
The continuous bio-manufacturing skid market is set for substantial growth in the upcoming years, with projections indicating it will reach $3.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast period is driven by factors such as the increasing implementation of fully continuous biologics production, rising investments in advanced bioprocess automation, a growing need for rapid scale-up capabilities, the broadening scope of cell and gene therapy manufacturing, and an intensified focus on cost-efficient biologics production. Prominent trends throughout the forecast period include the increasing uptake of continuous and integrated bioprocessing skids, escalating demand for modular and plug-and-play manufacturing systems, wider application of real-time process monitoring and control, the expansion of single-use continuous biomanufacturing platforms, and an enhanced emphasis on overall process efficiency and throughput.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28999&type=smp
What Significant Factors Are Influencing The Continuous Bio-Manufacturing Skid Market Expansion?
The escalating need for biopharmaceuticals is anticipated to stimulate the expansion of the continuous bio-manufacturing skid market in the future. Biopharmaceuticals are medical substances derived from biological origins, such as proteins, nucleic acids, or living cells, utilized for disease treatment, prevention, or diagnosis. This heightened demand for biopharmaceuticals is largely driven by the growing occurrence of chronic and genetic ailments that necessitate sophisticated biologic therapies for effective management. Continuous bio-manufacturing skids enhance biopharmaceutical manufacturing by enabling streamlined, automated, and scalable processes, thereby boosting efficiency, consistency, and speed in creating complex therapies. For instance, in January 2023, according to Cardinal Health Inc., the U.S. possessed 40 FDA-approved biosimilar products, with 25 available on the market. This represents an increase from January 2022, when 33 FDA-approved biosimilars were noted, and 21 were commercially accessible. Consequently, the rising demand for biopharmaceuticals is propelling the growth of the continuous bio-manufacturing skid market.
How Is The Continuous Bio-Manufacturing Skid Market Segmented Across Different Segment Categories?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
What Trends Are Shaping The Future Of The Continuous Bio-Manufacturing Skid Market?
Major companies in the continuous bio-manufacturing skid market are concentrating on developing innovative solutions, such as advanced biologics manufacturing platforms, to improve efficiency, scalability, and product quality. These next-generation biologics manufacturing platforms are sophisticated systems that enable fully connected, continuous production of biologics with real-time monitoring, greater efficiency, and consistent product quality. For instance, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, unveiled EnzeneX 2.0 at CPHI Milan 2024, which is the latest iteration of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented platform allows for seamless, uninterrupted processing from perfusion to the final drug substance. By employing high-titer clones and optimized cell media, it boosts productivity, increases target protein concentrations, and minimizes batch-to-batch variability. The system also incorporates process analytical technology (PAT) for real-time monitoring and control, ensuring consistent quality and operational efficiency, while simultaneously offering up to a 50% reduction in production costs per gram. These platforms deliver scalable, cost-effective biologics manufacturing that is adaptable to diverse modalities and media formulations.
Which Organizations Play A Role In The Continuous Bio-Manufacturing Skid Market Landscape?
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
Get The Full Continuous Bio-Manufacturing Skid Market Report:
Which Region Holds The Highest Market Share In The Continuous Bio-Manufacturing Skid Market?
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Continuous Bio-Manufacturing Skid Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Continuous Bio-Manufacturing Skid Market 2026, By The Business Research Company
Digital Biomanufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-biomanufacturing-global-market-report
Biopharmaceuticals Contract Manufacturing Market Report 2026
Bioengineering Technology Market Report 2026
https://www.thebusinessresearchcompany.com/report/bioengineering-technology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model